Ferritin subunits of heavy and light polypeptide chains self-assemble into a spherical nanocage that serves as a natural transport vehicle for metals but can include diverse cargoes. Ferritin nanoparticles are characterized by remarkable stability, small and uniform size. Chemical modifications and molecular re-engineering of ferritin yield a versatile platform of nanocarriers capable of delivering a broad range of therapeutic and imaging agents. Targeting moieties conjugated to the ferritin external surface provide multivalent anchoring of biological targets. Here, we highlight some of the current work on ferritin as well as examine potential strategies that could be used to functionalize ferritin via chemical and genetic means to enable its utility in vascular drug delivery.
Introduction
Medical goals for drug targeting are extraordinarily diverse. Potential utility of drug delivery systems transcends all medical specialties. Pathophysiological context and biological factors defining specifications for a suitable drug delivery system (DDS) are unique in every pathological condition and patient. Multitudes of natural, synthetic, and hybrid DDS using different principles and materials are needed for these purposes [1, 2] .
Among the key features are amenable routes of administration and delivery, therapeutic target, DDS and drug cargo and their featurespharmacokinetics, size, biocompatibility, durability, etc. In addition to these investigational parameters, important translational parameters to consider in designing an efficient targeted drug delivery system include amenability to scale-up, quality control and cost of production.
Natural carriers include biomolecules and their assemblies, as well as cells and their fragments. Biological nanoparticles assembled from natural or modified biomolecules exhibit various unique architectures and functional properties that render them strong contenders for targeted drug delivery. Numerous self-assembled biological nanoparticles exist in nature such as ferritin, virus-like particles (VLPs), heat-shock protein cages, chaperones, carboxysomes, and enzyme complexes [3] [4] [5] [6] [7] [8] [9] . These natural nanoparticles each provides a unique set of characteristics that could be applied in biotherapeutics.
Here we consider ferritin nanoparticles as carriers for vascular drug delivery. In this review we highlight some of the progress in the area of ferritin-based nanocarriers and their applications in therapeutics and imaging. Their potential as modular and stimuli-responsive drug delivery platform, as well as strategies for conjugation by genetic and chemical conjugation means will be discussed. Finally, we outline methods for pulmonary targeting, advancements in targeted pulmonary drug delivery systems, and the potential use for ferritin in pulmonary therapeutics and imaging.
Ferritin nanoparticles
Ferritin is a major iron-storage protein in the body consisting of 24 subunits that self-assemble to form spherical nanocages of around 12 nm in diameter with an interior cavity of 8 nm [10, 11] . Two types of subunits make up the ferritin nanocages, heavy (21 kDa) and light (19 kDa) chains [12, 13] . The proportion of these subunits varies in different tissues [14] . The heavy chain has catalytic ferroxidase activity that oxidizes Fe(II) to Fe(III) which is insoluble and nucleates at the core [15, 16] . Ferritin nanocages can load up to 4500 iron atoms in their interior cavity [12, 13] . Endogenous ferritin is a non-enzymatic antioxidant that plays a cytoprotective role inside the cells by sequestering iron and preventing its harmful pro-oxidative effects [17] .
Elevated serum ferritin levels have been observed during inflammatory conditions as well as in some cancers [18] . The primary role for circulatory ferritin is unclear, however it has been reported to bind to and be internalized by a range of cells. Human ferritin binding occurs preferentially via its heavy chain rather than light chain [19] .
The ferritin heavy chain interacts with the human transferrin receptor 1 (TfR1) leading to its endocytosis. This natural TfR1 targeting capability has been used to target TfR1-overexpressing cancer cells as a nanoparticle-assisted anti-cancer drug delivery strategy [19, 20] . Other ferritin receptors have been discovered in mice, such as T cell immunoglobulin and mucin domain protein-2 (TIM-2) which binds to heavy chain ferritin, and scavenger receptor class A, member 5 (SCARA5) which binds selectively to light chain ferritin. However, in humans, TfR1 remains as the primary ferritin receptor [19, 21, 22] .
Ferritin has quite a broad range of applications that span from therapeutics to imaging, diagnostics, bioelectronics, water purification, and even bioactuators for potential development as artificial muscle. The natural capacity of ferritin to encapsulate metals provides a platform that can be easily modified to give it unique functional characteristics. Biomineralization of ferritin with metals such as Co, Pt, Mn, Ni, and others have been used in bioelectronics because of their good electron transfer and storage capacity for development bionanobattery, biofuel cells, biosensors, and others [23] [24] [25] .
The iron-loading capacity of ferritin can also be used for complexation with oxyanions such as orthophosphates. The Dutch company BiAqua (www.biaqua.nl) has developed an innovative water treatment strategy using hyperthermophilic ferritin to adsorb oxyanion (phosphate and arsenic) water contaminants. This strategy circumvents the low affinity and biofouling issues that face other water purification strategies. Ferritin has even been proposed as a delivery platform in the nutritional field. Li M. et al. [26] developed calcium-loaded soybeen seed phytoferritin nanocages for use as edible calcium supplement. Encapsulation inside ferritin was to protect calcium ions from dietary absorption inhibitors such as tannic acid, oxalic acid, and zinc ions. Aside metal and mineral loading, ferritin has been incorporated into hydrogels for use as bioactuators with potential application in artificial muscle development. Nanocomposite hydrogel actuators were developed by embedding ferritin in poly(vinyl alcohol) (PVA) nanofibers. The ferritin acted to reinforce the nanofibers resulting in 230% increase in the elastic modulus compared to PVA hydrogels alone. Reversible bioactuation was observed by switching the pH, with contraction at pH 4 and expansion at pH 9 [27] .
Ferritin as modular drug delivery platform
Numerous groups have utilized the ferritin as a drug delivery platform by loading it with small molecule therapeutics and incorporating targeting moieties on the surface either chemically or genetically. Ferritin forms a natural self-assembled oligomeric protein complex with uniform size and structure amenable to chemical and genetic modification for attachment of various cargos and targeting moieties.
Some characteristics that make ferritin a promising drug delivery candidate include remarkable thermal stability (withstanding temperatures up to 80-100°C) and pH stability (pH 3-10), monodispersity, small uniform size, biocompatibility, biodegradability, low cost largescale production, hollow cavity (nanocage) with reversible assembly and disassembly for encapsulation of drugs and imaging agents, ease of conjugation by chemical procedures (ample surface area with reactive moieties for conjugation) and genetic means (reported genetic sequence available for modification by classic recombinant cloning strategies).
A number of groups have reported on ferritin as carrier for drug delivery. Ferritin-based nanotherapeutics have been developed by loading ferritin nanocages with small molecules such as doxorubicin [28, 29] , cisplatin [30] [31] [32] , curcumin [33] , carotenoids [34] , and cerium oxide [35] . Ferritin also provides robust strategy for metal nanoparticle encapsulation [36] [37] [38] . Strategies used drug loading include pH-or salt-induced disassembly/reassembly of ferritin, diffusion-based encapsulation, and direct conjugation of drug to ferritin surface (Fig. 1a) .
Some have incorporated certain functionalities into ferritin to make it more modular and hence a simpler modifiable platform (Fig. 1b) . In order to avoid complex chemical conjugation strategies, Kang H.J. et al. [39] incorporated Fc-binding peptide between the D and E helices of ferritin from hyperthermophilic archaeon, as modular ferritin platform for binding Fc-region of antibodies in a non-covalent and orientationspecific manner. The platform was used to complex with anti-HER2 trastuzumab antibody and an antibody against folate receptor, demonstrating cell-specific in vitro binding. Another modular apoferritin platform strategy developed by Hwang M.P. et al. [41] was to genetically incorporate His tag and protein G in apoferritin for detection of cancer biomarker. Apoferritin was combined with antibodies that interact with their Fc region to protein G, as well as nanoconstructs (such as quantum dots, gold nanoparticles, or magnetic nanoparticles) that were surface-functionalized with Ni-NTA derivatives for interaction with His-tags on apoferritin. Lee E.J. et al. [42] developed a ferritinbased siRNA delivery system called Proteinticles. Proteinticles were designed by genetically engineering human ferritin to display peptides on its surface such as cationic peptide (CAP) for binding siRNA, tumor targeting peptide, cell penetrating peptides, and an enzymatic cleavage site for releasing siRNA inside tumor cells. The poly-siRNA-proteinticle complexes demonstrated effective gene silencing in tumor cells. The modular apoferritin platform provides a simple strategy to switch between various cargo probes and antibodies.
Most ferritin drug delivery reports encapsulate the therapeutic agents which requires the breakdown of ferritin for drug release. In order to allow for rapid drug release from ferritin, Kwon C. et al. [40] site-specifically conjugated 24 β-cyclodextrins (β-CD) molecules per ferritin for potential loading of small hydrophobic molecules. Fluorescein isothiocyanate-adamantane (FITC-AD) was loaded onto a ferritin-coated β-CD molecule. The study revealed drug release half-life of 3 h, suitable for rapid drug delivery purposes, nonetheless release time could be increased with further fine-tuning.
Modifying ferritin to become stimuli-responsive adds greatly to its multifunctionality and controlled drug delivery capability. One group genetically modified ferritin to dissociate at pH 6 and reassemble at neutral pH. To do so, repeats of the GALA cell penetrating peptide were incorporated into E-helix truncated ferritin. The reversible transition of GALA from random coil to α-helix at acidic pH results in ferritin disassembly [43] . This may have applications in drug delivery, for inducible drug release at acidic pH as well as a method for drug loading in milder weak acid rather than the usual disassembly in a more damaging strong acid solution of pH 2.
For development of a multifunctional stimulus-responsive delivery system, Kang Y.J. et al. [44] incorporated thrombin cleavable peptide between the D and E helices of ferritin subunit. Thrombin cleavage induces the release of helix E and formation of 1.5 nm holes in the 4-fold axis of ferritin. A fluorophore was conjugated to the C-terminal genetically incorporated cysteine and NHS-PEG4-biotin was conjugated to the amine groups on the surface of ferritin for use as a targeting ligand for delivery to target cells over-expressing biotin receptors such as cancer cells. The fluorescent probe was released upon administration of thrombin. Various small molecules can be incorporated inside ferritin or genetically incorporated with peptides such as cytotoxic and apoptotic peptides for controlled release at target site.
Medical applications of ferritin
Ferritin has found wide-ranging utility in both therapeutics and imaging. The therapeutic applications of ferritin have primarily been focused on cancer therapy and vaccines.
Ferritin in cancer therapy
There are numerous studies on the use of ferritin for cancer therapy. Some have used the natural transferrin receptor targeting capability of ferritin to target transferrin-overexpressing cancer cells, while others have attached more cancer-specific targeting ligands. Falvo E. et al.
[31] demonstrated chemical conjugation of PEG-linked EP1 monoclonal antibodies onto ferritin for retargeting it to melanoma cells. The ferritin was loaded with cisplatin (~50/Ft particle) using pH-based disassembly/reassembly strategy, followed by conjugation with PEGantibody. The antibody conjugation led to 25-fold increase in specificity toward melanoma cells.
Another group genetically modified nanocages with RGD4C peptide and loaded them with doxorubicin for targeting αvβ3 integrin overexpressing tumor. Pre-complexation of doxorubicin with Cu(II) helped to increase the loading efficiency to up to 73 wt%. Increased circulation half-life, enhanced tumor growth inhibition, and decreased cardiotoxicity were observed compared to free doxorubicin [28] .
In a recent report, Huang X. et al. [45] developed a ferritin-based lung inhalation delivery system capable of rapidly penetrating lung mucus and targeting lung tumor tissue (Fig. 2) . Human ferritin was functionalized with different sized PEGs. FTn/FTn-PEG2k particles that contained both PEGylated ferritin subunits for mucus penetration and unPEGylated subunits for targeting tumor transferrin receptors demonstrated around 78% distribution on lung tracheal surfaces and was retained higher in upper airways 10 min after intratracheal administration. The FTn/FTn-PEG2k particles were then surface conjugated with doxorubicin molecules, which led to 60% survival after 60 days in a mouse lung cancer model as compared to untreated or free doxorubicin that led to median survival of 18 days.
In order to improve on the drug encapsulation and prevent leakage from ferritin, Luo Y. et al. [46] introduced negatively charged poly-Laspartic acid (PLAA) to absorb positively charged anti-cancer drug daunomycin (DN). Encapsulation of the PLAA/DN was carried out at pH 5 to induce swelling of the apoferritin hydrophobic channels. The drug loaded apoferritin was coated with hyaluronic acid to target hyaluronic acid receptor CD44 overexpressing lung cancer cells. In a recent study Zhang L. et al. [47] observed an active NLS-independent nuclear delivery of anticancer drug doxorubicin via H-chain apoferritin.
Rapid nuclear translocation was observed within 15 min. This has great significance for nuclear anticancer drug delivery, primarily its potential for evading drug resistance mechanisms of the cell such as enzymatic deactivation and drug efflux.
Ferritin in vaccines
There are a number of protein particle-based vaccines on the market mainly utilizing virus-like particles. Ferritin with its multimeric nature, ease of genetic modification, easy handing, and large-scale production, certainly has potential in vaccine development.
The self-assembling nature of ferritin was used to induce trimerization of influenza heamagglutinin (HA) viral proteins on surface of ferritin for development as an influenza vaccine. The ferritin used in this case was a non-haem ferritin from Helicobacter pylori. Immunization with the HA-ferritin nanoparticles resulted in tenfold increased antibody titer production compared to the trivalent inactivated influenza vaccine. Some advantages of these novel vaccines include the utility of simple recombinant protein production strategy that removes the need to express hazardous viruses in cell culture or eggs [48] .
Han J.A. et al. [49] utilized ferritin as an antigen delivery platform to dendritic cells for vaccine development. Ovalbumin-derived antigenic peptides OT-1 (CD8+ T cell epitope) or OT-2 (CD4+ T cell epitope) were incorporated at the C-terminus of ferritin. The OT-1 antigen-presentation on DC surface induced generation of antigen-specific cytotoxic effector T cells. The OT-2 antigen-presentation resulted in differentiation of CD4+ Th1 cells, which produced IFN-γ/IL-2 cytokines and CD4+ Th1 cells that produced IL-10/IL-13 cytokines. Incorporation of DC-targeting ligands and adjuvants is also being explored to further examine the ferritin-based antigen-delivery vaccine platform. 
Ferritin in bioimaging
One of the biggest applications of ferritin has been in the field of bioimaging. Multifunctional ferritin nanocages have been developed for fluorescence and MRI imaging of tumor cells. One example is the work by Li K. et al. [50] which genetically fused RGD targeting moiety and GFP fluorescent protein to the N-terminus of human heavy chain ferritin. The self-assembled fluorescent ferritin nanocages were loaded with iron oxide by incubation with iron and H 2 O 2 as oxidant. The iron oxide mineralized ferritin fusions were used to image α v β 3 integrin overexpressing tumor cells.
In order to make it a more multifunctional imaging system, Lin X. et al. [51] developed hybrid ferritin nanoparticles with activatable near-infrared fluorescence (NIRF) probes for tumor imaging. Two sets of ferritin were developed, one with Cy5.5 conjugated to matrix metalloproteinase (MMP) cleavable peptide, and the other with BHQ-3 quencher. The two sets of modified ferritin were disassembled in acidic pH and reassembled by bringing up the pH to form the hybrid ferritin nanoparticles. Upon administration of MMP-13, Cy5.5 was released and fluorescence was restored.
Hybrid ferritin nanoparticles were also developed incorporating RGD targeting moiety. In vivo animal study on tumor xenograft model demonstrated successful NIRF tumor imaging. Dual imaging of tumors has also been demonstrated using both NIRF and MRI imaging. Cy5.5 was conjugated to human heavy chain ferritin and loaded with iron oxide. The natural targeting capability of human ferritin to transferrin receptor 1 (TfR1) was used to target cancers overexpressing TfR1 [52] . The RGD targeting moiety has been incorporated on ferritin for imaging vascular inflammation and angiogenesis. Here the RGD was aimed to target vascular macrophages as well as angiogenic endothelial cells, which overexpress α v β 3 integrins. Therefore, NIRF imaging with Cy5.5 labeled RGD-ferritin could be applied to image macrophage-rich carotid lesions, as well as macrophages and angiogenic endothelial cells in abdominal aortic aneurysm lesions [53] .
In an innovative multimodal imaging system, Wang Z. et al. [54] developed a technique for loading radioisotopes inside ferritin for cancer theranostics (Fig. 3) . The copper sulfide ferritin nanocages were formed by incubating radioactive 64 CuCl 2 with ferritin, followed by addition of Na 2 S solution to form stable copper sulfide nanoparticles inside ferritin. The CuS-ferritin nanocages demonstrated excellent PET and photoacoustic imaging as well as high photothermal conversion for cancer photothermal therapy. A ferritin-based theranostic agent has been developed for treatment of hepatocellular damage in thioacetamide-induced acute hepatitis animal model. MRI contrast agent GdHPDO3A and curcumin known for its anti-inflammatory, antioxidant, and antineoplastic activities were encapsulated inside apoferritin. MRI was used to assess the drug delivery efficiency [33] . Other MRI contrast agents such as gadolinium have also been encapsulated inside ferritin. Aime S. et al. [55] used pHbased disassembly/reassembly to encapsulate Gd(III) chelate, GdHPDO3A. Around ten GdHPDO3A chelates were encapsulated inside apoferritin. Malino A. et al. [56] developed a more efficient encapsulation strategy by utilizing cationic gadolinium chelate GdMe 2 DO2A, which increased the number of gadolinium chelates encapsulated to 36.
An advanced ferritin-based MRI imaging strategy was developed by Shapiro M.G. et al. [57] who designed ferritin-based sensors for detection of protein kinase A (PKA) activity using MRI. Two sets of genetically modified ferritins were designed, one incorporating kinaseinducible domain (KID) and the other KIX domain from the activator protein CBP. In presence of the PKA enzyme, Ft-KID was phosphorylated and in turn bound to the Ft-KIX. This interaction resulted in clustering of the iron-loaded modified ferritin nanoparticles and enhancement of the T2 relaxation in MRI. These "smart" ferritin-based sensors have applications both in vitro and in vivo for monitoring enzymatic activity.
Conjugation strategies

Genetically encodable linkers
The most common strategy for protein-protein conjugation involves attachment of cross-linkers to the exposed amino groups on the protein, however there is not much control over the number of cross-linkers attached or the orientation of the conjugated protein. This lack of control over conjugation can lead to formation of cross-linked aggregates, a reduction or loss of function of the protein, or low-efficiency labeling. Genetic incorporation of linkers into proteins can lead to more effective development of bioconjugate therapeutics by enabling sitespecific conjugation in proper orientation. Numerous bioconjugation strategies (Fig. 4) have been developed utilizing genetically encodable peptide or protein tags. Some examples of encodable tags include His Tag (interacts with Ni-NTA), HaloTag (interacts with chloroalkane-linked moieties), SNAP-tag (interacts with benzylguanine derivatives), Clip-tag (interacts with benzylcytosine derivatives), SpyTag/SpyCatcher, sortase tag, biotin acceptor peptide (for enzymatic conjugation of biotin-linked moieties), and heterodimeric peptides [58] [59] [60] [61] . One simple bioconjugation strategy is the utilization of heterodimeric peptides that dimerize different proteins or moieties together. An example is the genetic tagging of scFvs and adenoviruses with leucine zipper coiled-coil heterodimeric peptides for attaching scFv antibody fragments onto adenoviruses in the same cellular supernantant from which they are released. Upon expression and release from the cell, the heterodimerization zipper domains induce the complexation of the scFvs moieties onto the adenovirus surface [62] . This strategy is especially suitable for adenoviruses, because their route of production and cellular release is different than the scFvs which require post-translational modification.
Homo-and hetero-dimerization peptides can also be used to design complex nanostructures. Gradisar H. et al. [63] formed tetrahedronshaped structures out of a single polypeptide consisting of 12 coiled-coil peptides. 3 homo-and 3 hetero-dimeric coiled-coil peptide pairs selfassembled to form the tetrahedron-shaped structure. Other more complex polyhedral structures could also be developed using such polypeptide origami.
Proteins can also be oligomerized using coiled-coil peptide motifs. Some examples of coiled-coil peptides include GCN4 leucine zippers (dimers), fibritin (trimers), tetrabrachion (teramers), and cartilage oligomerization matrix protein (pentamers) [64] [65] [66] [67] . In one case, Holler N. et al. [68] fused extracellular domains from receptors such as Fas and CD40 onto COMP pentamerization domain. The pentamerization resulted in greater solubility, high avidity, and enhanced ability to block FasL and CD40L. Another example is the development of bispecific decavalent single domain antibodies by fusing one set of single domain antibody to C-terminus of verotoxin B (VTB) pentamerization domain and the other set of single domain antibody to the N-terminus of VTB. These decabodies were designed to increase the avidity of the bispecific antibodies. Ferritin with its 24 subunits could potentially be used to provide a generous multimerization scaffold for single domain antibodies, to enhance the avidity and biological efficacy.
One promising site-specific conjugation is the use of bacterial-derived transpeptidase enzyme sortase to catalyze conjugation between proteins tagged with LPXTG motif and triglycine containing moieties. Chen Q. et al. [69] utilized the sortase-mediated conjugation to functionalize E2 protein cages. E2 protein subunits derived from the pyruvate dehydrogenase enzyme complex of Bacillus stearothermophilus self-assemble into 60mer protein cages of around 24 nm in size. A triglycine tag was incorporated at the N-terminus of E2 proteins which when fully assembled displayed 60 GGG tags available for sortasemediated conjugation. LPTEG containing β-galactosidase or endogluconase enzymes and thermoresponsive elastin like polypeptides (ELP) were conjugated using sortase. The thermoresponsive ELPs were used as a simple temperature-based purification strategy.
A notable novel conjugation strategy is the SpyTag (peptide) and SpyCatcher (protein) based conjugation mediated by the SpyLigase enzyme leading to irreversible isopeptide bond formation. Fierer J.O. et al. [70] used the SpyTag/SpyCatcher strategy to develop a linearized polymer of affibodies to enhance the capture of circulating tumor cells. A SpyTag and a KTag (derived from SpyCatcher) in presence of SpyLigase polymerized end to end forming a polymer of more than 20 affibodies. Magnetic beads coated with the multivalent polymeric affibodies increased the capture of circulating cancer cells displaying low number of tumor antigens. Building on the the SpyTag/SpyCatcher technology, Fairhead et al. [71] developed chimeric SpyAvidin hubs to create modular protein nanoassemblies. The strategy combined SpyTag or SpyCatcher with streptavidin components to create SpyAvidin octamer or eicosamer protein architecture. The eicosamer nanoassembly was used to cluster MHC-peptide complexes for T cell stimulation, and was found to be superior to the conventional MHC tetramers.
Other bioconjugation strategies include incorporation of split-inteins, biotin acceptor peptides, and monovalent streptavidin. Inteinmediated conjugation is a process whereby N-and C-terminal halves of intein-containing proteins or molecules can be fused together by a process of protein splicing where the split inteins interact and self-excise, conjugating the two target molecules together [72, 73] . Monovalent streptavidin is another recently introduced tagging moiety that can allow for more controlled site-specific conjugation rather than the original tetrameric streptavidin that is prone to aggregation as a result of its multivalent nature [74] . Genetic incorporation of biotin acceptor peptide (AP) in the protein of interest has also been tried for sitespecific conjugation. The biotin ligase (BirA) enzyme derived from Escherichia coli has been used to biotinylate the acceptor peptide tagged proteins. One example is the incorporation of AP peptide on AMPA receptors on neurons for biotinylation and targeting with streptavidincoated quantum dots for visualizing the localization of the receptors in live neuron synapses [75] .
Chemical conjugation
The functional groups present on proteins can be used for conjugation of various moieties (Fig. 4) . Some of the amino acid side-chain groups used for conjugation include amino group on lysine, thiol on cysteine, carboxylic acid on aspartic acids and glutamic acids, and hydroxyl moiety on tyrosine. Numerous heterobifunctional crosslinkers have been developed for protein conjugation. Primary amines on proteins can be conjugated to carboxylic acids on another protein using 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC) crosslinkers typically in combination with N-hydroxysuccinimide (NHS) that reacts with the carboxyl group and creates a more stable intermediate that then reacts with the primary amines [76] [77] [78] .
Utilizing the crosslinker EDC along with N-hydroxysuccinamide (NHS), Andrade S. et al. [79] conjugated ghrelin to virus-like particles (VLPs) derived from Bluetongue virus (BTV). The anti-ghrelin vaccine was developed as strategy for treatment of obesity. Sulfhydryl functional groups can be introduced by heterobifunctional crosslinkers, such as N-succinimidyl S-acetylthioacetate (SATA) that reacts with primary amine on proteins [80, 81] . Following the NHS conjugation to amines, the thioacetate is deprotected to display sulfhydryl group for reaction with thiol reactive compounds such as maleimides. The SATA reaction is typically coupled with corresponding heterobifunctional crosslinker sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (sulfo-SMCC) that displays maleimides on target protein that is being conjugated. The SATA and SMCC is a common and simple crosslinking reaction for conjugating proteins together. This strategy has been used by us and others to conjugate various antibody and antibody fragments onto the ferritin surface [82] [83] [84] [85] [86] .
For a more site-specific introduction of sulfhydryl groups, cysteines can be genetically introduced into the protein for site-selective conjugation. Such strategy can be used to introduce cysteines selectively on the exterior or interior of ferritin for attaching cargo or targeting moieties on the surface or interior of ferritin. VLPs have been also been modified using similar strategy. Peacey M. et al. [87] modified VLPs with sulfo-SMCC followed by conjugation to thiol containing peptides or to SATA treated proteins. Cytokine and antibody conjugations have also been carried out with the SATA and SMCC strategy. Li J. et al. [88] chemically conjugated recombinant human interleukin 2 protein with a monoclonal antibody. Functional IL-2 cytokine activity and the binding capacity of the antibody were both preserved using this conjugation strategy.
"Click" coupling reactions between azides and alkyne functional groups provide a simple and efficient bioconjugation strategy compatible with a broad range of temperatures, pH values, and solvents. One of the most popular click reactions is the Huisgen 1,3 dipolar-cycloaddition in presence of Cu(I) catalyst [89] [90] [91] . Azide and alkynes can be chemically incorporated on the protein of interest or introduced genetically via incorporation of unnatural amino acids. Patel K.G. et al. [92] incorporated unnatural methionine analogues azidohomoalanine and homoproparglyglycine into bacteriophage MS2 and Qb VLPs. The unnatural amino acids were then conjugated to azide and alkyne containing proteins such as scFv antibody fragments, granulocyte-macrophage colony stimulating factor (GM-CSF), immunostimulatory CpG DNA, and PEG. The methionine residues were globally replaced with the unnatural amino acids in a cell-free system rather than the methionine auxotrophic E. coli, demonstrating high yield and efficient incorporation of the unnatural amino acids.
Another interesting strategy that has been used to increase the cargo loading capacity of protein cages is the site-specific initiation of atomtransfer radical polymerization to form amine rich polymer inside the protein cage. The primary amine groups inside the cage provide conjugation sites for cargo attachment. Lucon J. et al. [93] used this strategy to enable high density loading of a gadolinium MRI reagent inside P22 virus-like particles.
Ferritin carriers for drug delivery to the pulmonary vasculature
Pulmonary targeting
Pulmonary vasculature is an important therapeutic target in many disease conditions, yet targeting ferritin to the pulmonary endothelium has not been explored. In our lab, we have addressed this novel aspect, using targeting strategy designed by us and others, i.e., conjugating carriers with antibodies and antibody fragments binding to endothelial surface determinants ("vascular immunotargeting").
Examples of such ligands (Table 1 ) include antibodies to plateletendothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), angiotensin-converting enzyme (ACE), aminopeptidase P (APP), and plasmalemma vesicle protein-1 (PV1) [94] . Platelet-endothelial adhesion cell molecule-1, (PECAM-1/CD31) is constitutively expressed by the endothelium at 0.2-2 × 10 6 copies per cell [95] . It is mainly localized on the endothelial intercellular junctions. Anti-PECAM-1 antibody conjugated nanocarriers have been shown to accumulate in the lung and inhibit the endothelial inflammatory response [96] . Intercellular adhesion molecule-1, CD54 (ICAM-1) is constitutively expressed on the apical endothelial plasmalemma and is upregulated upon inflammation. On the other hand, vascular cell adhesion molecule-1 (VCAM-1) is expressed primarily only upon inflammation. Another interesting target is PV1 which has been reported to be enriched in pulmonary endothelial cells [97] [98] [99] .
In addition to cell-specific delivery, subcellular targeting could be used to enhance the effectiveness of therapeutics. Incorporation of a subcellular targeting mechanism into the nanocarrier system could be used to direct the therapeutic to caveolar endosomes, to potentially more efficiently suppress the redox-active endosomes or the signaling endosomes which contain NADPH oxidases involved in inflammation and vascular oxidative stress. From our studies on pulmonary targeted drug delivery systems, a comparison of pulmonary targeted ICAM-1 and PECAM-1 nanoparticles demonstrated the superiority of the ICAM-1 targeted ferritin nanoparticles in lung targeting (Fig. 5) . The anti-ICAM Ab/FNPs demonstrated a remarkable 160.9 ± 6.5% ID/g lung targeting, which is superior to the other tested nanocarriers.
Potential application in pulmonary medicine
Ferritin nanoparticles, with their uniform size, stability, and biocompatibility, show promise as a therapeutic delivery platform with potential for translation to the clinical domain. Numerous small Table 1 Examples of endothelial determinants for targeting nanocarriers to the pulmonary vasculature. molecule anti-inflammatory, antioxidant, or other therapeutic agents can be potentially encapsulated inside ferritin or attached on the ferritin surface (Table 2 ). Targeting ferritin-based therapeutics to pulmonary endothelium could have great potential for treatment of various oxidative and inflammatory pulmonary conditions. The pulmonary vasculature is an important target for therapeutic delivery. Elevated reactive oxygen species (ROS) generated by enzymes such as NADPH oxidases in pulmonary endothelial cells has been found to be involved in vascular oxidative stress and the proinflammatory cascade that manifests into pathological conditions such as acute respiratory distress syndrome (ARDS) [104, 105] . Targeted delivery of therapeutics such as ROS-detoxifying interventions to the pulmonary endothelium could protect from oxidative damage and suppress pulmonary inflammation. Antioxidant enzymes have been conjugated to endothelial-specific antibodies as ROS-detoxifying intervention [96, [106] [107] [108] [109] [110] [111] .
Platelet-endothelial adhesion cell molecule-1, CD31 (PECAM-1) antibody conjugated SOD or catalase nanoparticles have led to endothelial protection against ROS-induced injury such as ischemia/reperfusion, lung transplantation or inflammation [106] [107] [108] . Anti-PECAM-1 antibody conjugated nanocarriers have been shown to accumulate in the lung, and exhibit inhibition of endothelial inflammatory response. Kozower B.D. et al. [109] demonstrated PECAM-targeted delivery of catalase enzyme to pulmonary vasculature and retention of catalase activity during cold storage and transplantation in an in vivo lung transplantation model.
Exploring an inhalation delivery system, Yen C.C. et al. [112] delivered aerosolized recombinant human extracellular superoxide dismutase enzyme in prevention of hyperoxia-induced lung injury. The study demonstrated increased survival rate, decreased lung edema, and greater protection from systemic oxidative stress. The aerosolized SOD delivery strategy was proposed as an effective method of delivering SOD to critically ill patients in intensive care units for protection against oxygen toxicity, with therapeutic applications for acute respiratory distress syndrome.
Endothelial targeted immunoliposomes have been used for therapeutic delivery of small molecule and proteins therapeutics to pulmonary vasculature. Hood E.D. et al. [113] loaded PECAM-1 antibodycoated PEG-liposomes with MJ33, an NOX inhibitor. MJ33 acts by inhibiting cytosolic phospholipase 2 (PLA 2 ), suppressing production of lyso-phospholipids and free fatty acids involved in NOX activation. The immunoliposomes inhibited expression of proinflammatory marker VCAM, decreased vascular permeability, and reduced alveolar edema by around 50%. These immunoliposomes have also been used to deliver EUK-134, a SOD/catalase mimetic. Suppression of inflammation and protection greater than 60% against pulmonary edema was observed in LPS-challenged mice [101] . Other examples of small molecule anti-inflammatory agents used with immunoliposome mediated delivery to lung, include delivery of dexamethasone [114] and prostaglandin E1 [115] .
Nitric oxide (NO) with its anti-inflammatory and vasodilator properties has been used for treatment acute lung injury, primarily in inhaled form. Gaseous nitric oxide has been reported to alleviate acute lung injury by decreasing inflammation, increasing pulmonary vasodilation, and enhancing gas exchange, however it can also lead to unfavorable byproduct formation such as nitrites, nitrates, peroxynitrates, and other reactive oxygen species that can be damaging to the lung [116, 117] . In order to prevent the damaging effects of inhaled NO, NOreleasing prodrugs have been developed such as NO/nucleophile adducts (NONOates). Kirov M.Y. et al. [118] developed biodegradable linear polyethyleneimine-based NONOates (L-PEI-NONO). Aerosolized L-PEI-NONO was found to decrease pulmonary hypertension and lung edema, as well as increase gas exchange in endotoxin-induced acute lung injury model. Moreover, NONOate was shown to attenuate antiinflammatory effects of PECAM-targeted SOD [119] .
Pulmonary delivery of anti-inflammatory cytokines or inhibitors of inflammatory cytokines also has therapeutic potential in treatment of ARDS. Exogenous delivery of IL-10 cytokine has been found to decrease hyperoxia-induced lung injury. Decreased levels of myeloperoxidase, IL-6, TNF-α, MIP-2, iNOS, as well as decreased lung permeability and increased survival in mice were observed [120] . Pro-inflammatory cytokines such as TNFα and IL-1 play a major role in endothelial activation and vascular dysfunction. Alveolar macrophages have been reported to be a major source for IL-1 in ARDS. Antagonists against proinflammatory cytokines could help in treatment of ALI. Frank J.A. et al. [121] demonstrated protective effect of IL-1 receptor antagonist (Il1Ra) in ventilator induced lung injury (VILI) mouse model, showing decreased pulmonary edema and reduced neutrophil recruitment. Attenuation of VILI has also been demonstrated by intratracheal delivery of single domain antibody against p55 TNF receptor [122] .
Numerous therapeutic agents are available for pulmonary targetedferritin based delivery. The potential of this delivery system lies with the amount of therapeutic agent that can be encapsulated or conjugated to the surface without jeopardizing the targeting efficiency. Some groups have reported dense loading of therapeutic or imaging agents [28, 93] . If the same high drug loading can be achieved with pulmonary therapeutic agents while maintaining efficient targeting, then this would open the door for translation of ferritin-based therapeutics into pulmonary medicine.
Challenges associated with ferritin
Notwithstanding emerging opportunities for ferritin-based drug delivery, we must pay attention to potentially problematic issues. The challenges as with most other nanocarriers include achieving optimal homogeneity, reproducibility, cargo loading capacity, targeting efficiency, pharmacokinetics, biocompatibility, ease of manufacturability, and cost-effectiveness. With the advances in genetic engineering and site-specific controlled conjugation strategies, there are numerous options available for incorporation of cargoes and targeting ligands in a more site-specific and orientation-specific manner, and at higher yield. The challenge that is critical for development ferritin formulations with high therapeutic efficacy is how to enhance the number of targeting ligands and cargoes in a manner such that they do not interfere with the loading of each other. This has been investigated by us, where increasing the surface conjugation of therapeutic protein (superoxide dismutase) resulted in decreased conjugation of antibodies and reduced targeting efficacy, as compared to encapsulation of the therapeutic protein which preserved the high targeting efficiency. In addition, the small size of ferritin has its advantages in certain targeting applications, however it also limits the number of antibodies or cargoes that can be loaded. Genetic modifications could be made to potentially alter the ferritin size to accommodate more targeting ligands and cargoes. As with any drug delivery carrier, the biological challenges include adverse and unintended effects associated with impairment of the target and clearing cells and tissues, abnormal host defense reactions, derangement of reactive cascades of coagulation and complement in blood and other abnormalities. These undesirable reactions may ignite side effects. Further, drug delivery is likely to be intended for use in patients, not healthy people. Pathological factors typical of the disease may aggravate the response to ferritin carriers. For example, cytokines and other mediators of ongoing inflammation may aggravate the immune reaction to ferritin.
One concern general to biotherapeutics drugs and biological carriers is immune reactions. Both immunological theory and clinical practice imply that administration of biological materials in experimental mammalian animals and human patients may elicit immunological responses including activation of subsets of lymphocytes and production of antibodies and that this reaction is expected to be aggravated by using heterologous biomolecules from a different species. Human-antimouse IgG response provides a well-known example of this immunological reaction. Of note, immune reactions to non-biological carriers have also been reported, such as antibodies to PEG in humans [123] [124] [125] [126] . Furthermore, use of "human" agents such as recombinant proteins is complicated with inevitable denaturing of a fraction of these reagents during the production, leading to exposure of normally hidden residues and epitopes. In addition, there is an issue of undetectable yet potentially active contaminants from the producing systems (not limited to endotoxin). Therefore, unintended immune responses represent common serious concerns for all drug delivery strategies. There are following avenues to address these concerns.
First is the use of human ferritin platforms or strategies to "humanize" ferritin from other species, such as by replacing most immunogenic residues and epitopes by human sequences and scaffolds, or total, achieved by replacing a heterologous component by human analogues. Second, increase in efficacy and specificity of targeted delivery will lead to dose reduction, hence alleviation of immune response. Third, studies by Hubbell and other labs suggest that some versions of molecular configuration of immunogenic molecules in a drug delivery system confers tolerance [127, 128] . Fourth, in lifethreatening conditions, treatment with potentially immunogenic yet needed drug delivery systems can be accompanied by immunosuppressive agents. Finally, in many acute conditions, the envisioned mode and regimen of administration i.e., single injection or infusion avoiding repetitive injections, will likely minimize immune response.
Conclusion
Ferritin is a biological "ready-to-use" nanoparticle with unique properties that could be exploited for use in imaging and therapeutics of pulmonary diseases. The protein exhibits natural capacity to encapsulate a range of metals and minerals, as well as imaging agents and therapeutics. Ferritin is highly versatile and amenable to various genetic and chemical modifications that can be used for incorporation of targeting moieties or therapeutic cargo. Numerous modifications can be carried out to make ferritin more modular and stimuli-responsive to simplify the construct assembly and enhance its therapeutic efficacy.
Ferritin has strong potential to make an efficient targeted drug delivery and imaging platform for clinical translation. One main factor that needs to be evaluated more thoroughly to determine its clinical practicality is its biocompatibility. Our recent in vivo animal biodistribution studies of pulmonary vascular immunotargeting have shown high pulmonary endothelial targeting with no noticeable undesired effects. These natural bio-nanoparticles could be easily modified and functionalized to treat various oxidative and inflammatory pulmonary conditions. The next phase of pulmonary therapeutic evaluation will determine its true place in clinical pulmonary drug delivery.
